Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to $84000.0.

  • Jaguar Health's Other Working Capital Changes rose 10873.18% to $84000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $669000.0, marking a year-over-year decrease of 8365.9%. This contributed to the annual value of $1.5 million for FY2024, which is 6980.64% down from last year.
  • Latest data reveals that Jaguar Health reported Other Working Capital Changes of $84000.0 as of Q3 2025, which was up 10873.18% from $286000.0 recorded in Q2 2025.
  • Jaguar Health's Other Working Capital Changes' 5-year high stood at $3.6 million during Q2 2023, with a 5-year trough of -$1.2 million in Q3 2023.
  • For the 5-year period, Jaguar Health's Other Working Capital Changes averaged around $512578.9, with its median value being $286000.0 (2025).
  • The largest annual percentage gain for Jaguar Health's Other Working Capital Changes in the last 5 years was 66881.03% (2023), contrasted with its biggest fall of 207966.1% (2023).
  • Quarter analysis of 5 years shows Jaguar Health's Other Working Capital Changes stood at -$573000.0 in 2021, then skyrocketed by 154.28% to $311000.0 in 2022, then soared by 668.81% to $2.4 million in 2023, then tumbled by 107.95% to -$190000.0 in 2024, then surged by 144.21% to $84000.0 in 2025.
  • Its last three reported values are $84000.0 in Q3 2025, $286000.0 for Q2 2025, and $489000.0 during Q1 2025.